| Eptinezumab 100 mg | Eptinezumab 300 mg | Eptinezumab 1000 mg | Placebo |
---|---|---|---|---|
N = 701 | N = 695 | N = 81 | N = 791 | |
Total Time in Clinical Study, n (%) | ||||
  ≥12 weeks | 680 (97.0) | 681 (98.0) | 78 (96.3) | 766 (96.8) |
  ≥24 weeks | 642 (91.6) | 649 (93.4) | 46 (56.8) | 692 (87.5) |
  ≥36 weeks | 288 (41.1) | 293 (42.2) | N/A | 280 (35.4) |
  ≥48 weeks | 263 (37.5) | 270 (38.8) | N/A | 256 (32.4) |